Patient access, supply chain, adherence, and comorbidities are only a few of the challenges associated with oral anticancer agents, which are included distributed by specialty pharmacies.
The past decade has seen a surge in oral cancer therapies. These agents—representing approximately 25% of all new anticancer drugs in development—provide benefits as well as present new challenges.
Many of these oral agents are distributed through specialty pharmacies, in part because they require proof of Risk Evaluation and Mitigation Strategies compliance. Joseph Bubalo, PharmD, an oncology pharmacy specialist at Oregon Health & Science University, in Portland, estimates that almost half of all oral cancer agents move through specialty pharmacies. Thus, supply channel issues are often at the top of the list of challenges to resolve, not the least of which is access. For example, will a new oral chemotherapy drug even be available to patients at a given hospital or clinic, or do limited distribution networks pose barriers to access?
Read the complete article at ClinicalOncology News: http://bit.ly/1DPKqbL
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Health Care Utilization and Cost of Diagnostic Testing for Respiratory Infections
September 17th 2025Syndromic reverse transcriptase–polymerase chain reaction tests for respiratory infections were associated with lower health care resource utilization and costs, implicating potential for improved value in patient care.
Read More
Cumulative Atropine Not Associated With Increased Risk of Ocular Events in Children With Myopia
September 17th 2025Although children living with myopia taking atropine did experience an increased incidence of cataracts, glaucoma, or maculopathy, it is unclear if this risk was confounded by myopia severity.
Read More